Equity research analysts tracking Equillium Inc. (NASDAQ: EQ) maintain generally favorable consensus ratings reflecting optimism around its clinical pipeline milestones, though multi-year price forecasts vary widely among institutional forecasters. Predictions range from conservative downward adjustments to bullish target expectations, depending heavily on upcoming clinical trial readouts and partnership developments.